Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Businesswire News Releases

Mar 28, 2024 08:30 ET
Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 2024
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting. Highlighting its latest research, the company will present ten posters covering a broad spectr...
Mar 28, 2024 08:30 ET
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease....
Mar 28, 2024 08:30 ET
HCA Healthcare Releases 2024 Annual Impact Report
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced the release of its annual Impact Report that reflects on the past year and highlights HCA Healthcare’s positive impact across the communities it serves....
Mar 28, 2024 08:30 ET
Latch Launches Door Property Management and Announces the Acquisition of The Broadway Company’s Property Management Division
Latch, Inc., soon to be Door.com, today announced the launch of its property management division, Door Property Management, LLC (DPM...
Mar 28, 2024 08:30 ET
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. (“Veranex”) to assist with the development of the company’s next generation UroShield and PainShield products....
Mar 28, 2024 08:30 ET
NiSource Announces Leadership Changes in Ohio and Indiana Subsidiaries
NiSource (NYSE: NI) today announced that Robert Heidorn will replace Vince Parisi as president and chief operating officer of Columbia Gas of Ohio. Parisi, who was previously identified as the interim president of the Indiana-based subsidiary NIPSCO, has formally been named president and chief operating officer of NIPSCO....
Mar 28, 2024 08:30 ET
OSI Systems Receives $5 Million Order for Advanced CT Security Screening Systems at a Major European Airport
OSI Systems, Inc. ("OSI Systems" or the "Company") (NASDAQ: OSIS) announced that its Security division received a $5 million order to provide 920CT baggage screening technology for passenger checkpoints at a leading European international airport....
Mar 28, 2024 08:30 ET
Special Committee of Bally’s Retains Financial and Legal Advisors in Connection With Standard General’s Proposal
The special committee of independent and disinterested directors (the “Special Committee”) of Bally’s Corporation (“Bally’s” or the “Company”) (NYSE: BALY) formed to evaluate the preliminary, non-binding acquisition proposal from Standard General, dated March 11, 2024 (the “Proposal”), among other things, today announced that it has retained Macquarie Capital as its financial advisor and Potter Anderson & Corroon LLP and Sullivan & Cromwell LLP as its legal counsel in connection with its evaluation of the Proposal, as well as any potential strategic alternatives to the Proposal....
Mar 28, 2024 08:30 ET
The Marriott Vacation Clubs™ Announces Expanding City Collection With New Waikiki Property Now Open for Booking
The Marriott Vacation Clubs™, a portfolio of vacation ownership brands operated by Marriott Vacations Worldwide (NYSE: VAC), understands there is a difference between visiting a city and seeing it...
Mar 28, 2024 08:30 ET
Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call....
Mar 28, 2024 08:21 ET
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction....
Mar 28, 2024 08:20 ET
Global Floating Data Center Industry Report 2023-2033 Featuring Key Players - Nautilus Data Technologies, Beijing Highlander Digital Technology, Subsea Cloud, Denv-R, Microsoft, Keppel Data Centres -
The "Floating Data Center Market - A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering....
Mar 28, 2024 08:08 ET
$84.2 Bn Highly Potent API Market - Global and Regional Analysis and Forecast, 2023-2033 - Oncology Segment to Lead - ResearchAndMarkets.com
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.c...
Mar 28, 2024 08:06 ET
Slip Robotics Wins Best New Innovation in the Supply Chain at MODEX 2024
Slip Robotics, a warehouse robotics company, was presented with the MHI Innovation Award for Best New Innovation for its SlipBot ALR (automated loading robot). This award was announced at MODEX 2024, North America's largest supply chain and material handling conference, with more than 1,200 exhibiting companies and 48,000 attendees in Atlanta, Georgia....
Mar 28, 2024 08:05 ET
Fresh Del Monte Named One of America’s Most Trusted Companies by Newsweek for the Third Consecutive Year
Fresh Del Monte Produce Inc. (NYSE: FDP), one of the world’s leading vertically integrated producers, distributors, and marketers of fresh and fresh-cut fruits and vegetables, has been named
Mar 28, 2024 08:05 ET
Recommended Cash Offer by Keysight for Spirent Communications PLC
Keysight Technologies (NYSE: KEYS), today announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications PLC (London Stock Exchange Symbol: SPT) ("Spirent”) for a cash consideration of 199 pence per Spirent share which values Spirent at approximately £1,158 million (US$ $1,463 million1), on a fully diluted basis. Spirent shareholders will also be entitled to receive a special dividend of 2.5 pence per Spirent share, in lieu of any final dividend for the year ended 31 December 2023 (together with the cash consideration of 199 pence per s...
Mar 28, 2024 08:02 ET
VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May)....
Mar 28, 2024 08:01 ET
South Africa Motor Vehicle Industry Report 2023: Muted Domestic Sales and Export Slowdown Propose Challenges - ResearchAndMarkets.com
The "The Motor Vehicle Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering....
Mar 28, 2024 08:00 ET
Announcement Regarding Possible Offer
The Board of MariaDB plc (NYSE: MRDB) (“MariaDB” or the “Company”) confirms that on March 26, 2024, it received an unsolicited non-binding indicative proposal from Progress Software Corp. (“Progress”) to acquire the entire issued and to be issued share capital of the Company (the “Possible Offer”). Progress provides software that enables organizations to develop and deploy their mission-critical applications and experiences, as well as effectively manage their data platforms, cloud and IT infrastructure. Progress publicly announced such offer on March 26, 2024. The ...
Mar 28, 2024 08:00 ET
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD). Data from 10 abstracts will be featured at the upcoming...